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Several studies (6, 7) have shown that, whereas 99m Tc-sestamibi uptake decreases with a reduction in resting MBF, it does not increase significantly in the normal myocardium during pharmacologically induced hyperemia. Thus MBF mismatch alone cannot explain the occurrence of a reversible perfusion defect distal to a coronary stenosis or the high sensitivity and specificity of 99m Tc-sestamibi perfusion imaging for the detection of coronary artery disease during pharmacological vasodilatation (23, 26, 27) .
We (30) and others (3, 4) have previously shown that in the absence of a stenosis, coronary vasodilators increase MBF velocity without changing myocardial blood volume (MBV), which is the volume of blood resident within myocardial microvessels (vessels Յ 200 m in diameter). We also demonstrated that, whereas MBV distal to a noncritical stenosis remains unchanged at rest, it decreases during pharmacologically induced coronary hyperemia (13) . Furthermore, the magnitude of decrease in MBV correlates closely with the severity of stenosis and occurs to maintain a constant capillary hydrostatic pressure (12, 13) .
We, therefore, hypothesized that reversible 99m Tcsestamibi perfusion defects during pharmacologically induced coronary vasodilatation occur because of a reversible decrease in MBV distal to a stenosis. Because ϳ90% of the MBV is resident in capillaries (16) , the decrease in MBV would reduce the capillary surface area available for 99m Tc-sestamibi uptake during hyperemia compared with that available at rest, resulting in a reversible perfusion defect. We tested our hypothesis in an open-chest canine model under the following conditions: 1) increases in MBF in the absence of changes in MBV, 2) decrease in MBV despite an increase in MBF, and 3) reduction in both MBF and MBV.
METHODS
Animal preparation. The study protocol was approved by the Animal Research Committee at the University of Virginia and conformed to the American Heart Association Guidelines for Use of Animals in Research. Thirty open-chest anesthetized dogs were used for the study. Catheters were placed in both femoral veins for administration of fluids and microbubbles and in both femoral arteries for duplicate reference arterial sample withdrawal for radiolabeled microsphere analysis. A catheter was inserted into the right atrium via the right external jugular vein for the measurement of right atrial pressure.
Proximal portions of the left anterior descending (LAD) and left circumflex (LCx) coronary arteries were dissected free from the surrounding tissue. Ultrasonic time of flight flow probes (series SB, Transonics) were placed around these arteries and connected to a flowmeter (model T206, Transonics). Catheters were positioned in the ascending aorta via the right carotid artery for measurement of central aortic pressure as well as in the left atrium for pressure measurement and for injection of radiolabeled microspheres. A 20-g Teflon catheter was placed distal to the artery undergoing either subselective adenosine infusion or placement of a stenosis. In the latter setting, it was also used to measure distal coronary artery pressure. All catheters were connected to pressure transducers, which, like the flowmeter, were connected to a multichannel recorder (model ES 2000, Gould Electronics).
In group I (n ϭ 10 dogs), the purpose was to evaluate regional 99m Tc-sestamibi uptake during increases in MBF without changes in MBV. MBF in the LAD bed was increased to different levels using various doses of adenosine administered subselectively into the LAD in separate dogs (Fig. 1) . In group II (n ϭ 13 dogs), regional 99m Tc-sestamibi uptake was measured when MBF was increased to different degrees in both coronary arteries from a left main infusion of adenosine while MBV in one bed was decreased distal to a noncritical stenosis (Fig. 2) . In group III (n ϭ 7 dogs) regional 99m Tcsestamibi uptake was assessed when both resting MBF and MBV were reduced with a flow-limiting stenosis. Coronary driving pressure (CDP) was measured as the difference between mean aortic (or distal coronary in case of stenosis) pressure and right atrial pressure. Myocardial vascular resistance (MVR) was calculated by dividing CDP by the mean coronary blood flow.
Ex vivo 99m Tc-sestamibi imaging and measurement of myocardial activity. Approximately 8 mCi of 99m Tc-sestamibi (DuPont Pharmaceuticals) was injected intravenously in each dog. At the end of the experiment, the heart slice corresponding to the MCE image (1 cm thick) was placed on the center of the scan head of a gamma scintillation camera (Technicare 420, Ohio Nuclear) to obtain an ex vivo image. An all-purpose medium energy collimator with a 20% energy window centered around the 140-keV peak of 99m Tc was used. Images were acquired in a 128 ϫ 128 matrix with collection of 1 ϫ 10 6 counts for each acquisition. After the ex vivo imaging was completed, the heart slice was divided into 16 segments. Each segment was further divided into epi-, mid-, and endocardial thirds. Because there is no means of assessing changes in absolute myocardial 99m Tc-sestamibi uptake between dogs, a piece of skeletal muscle was also taken from the hindlimb and divided into 12 segments to serve as a control against which to compare myocardial 99m Tc-sestamibi uptake. Because adenosine was administered directly into the coronary artery, it was assumed not to affect skeletal muscle blood flow. Regional myocardial and skeletal muscle 99m Tc-sestamibi uptake were measured using a gamma well counter (LKB Wallac). Tc activity. MBF to each epi-, mid-, and endocardial piece was calculated from the equation Q m ϭ (C m ϫ Q r )/C r , where Q m is blood flow to the myocardial piece (in ml/min), C m is tissue counts, Q r is the rate of arterial sample withdrawal (in ml/min), and C r is arterial reference sample counts (11) . Transmural MBF (in ml ⅐ min Ϫ1 ⅐ g Ϫ1 ) to each of the 16 wedgeshaped segments was calculated as the quotient of the summed flows to the individual pieces within that segment and their combined weight. To exclude the effect of collateral MBF on the lateral borders of the perfusion bed, we calculated MBF to each bed (defined by Monastral blue dye injection, see Experimental protocol) by averaging the transmural MBF in the central 50-75% segments in each bed.
Myocardial contrast echocardiography. Myocardial contrast echocardiography (MCE) was performed using intermittent harmonic imaging as previously described (30) . All system settings were optimized at the beginning of each experiment and held constant throughout. A solution consisting of 2 ml of Optison (Mallinckrodt Medical) diluted in 23 ml of normal saline was infused into the femoral vein at a rate of 80-100 ml/h. Imaging was initiated after a steady-state concentration of microbubbles was achieved (ϳ2 min after initiating infusion). Ultrasound transmission was gated to the electrocardiogram. All pulsing intervals (PI) greater than one cardiac cycle (ranging from 1 to 20) were obtained using a single trigger positioned at end systole (peak of the T wave). Dual triggers (the "imaging trigger" was placed at end systole and the "microbubble destruction" trigger was placed 200-400 ms before the imaging trigger) were used to obtain PI less than one cardiac cycle. Up to seven end-systolic images were acquired at each PI.
Images were transferred from a videotape to an offline image analysis system. At least five images from each PI were selected and aligned using computer cross-correlation along with five background images acquired before infusion of microbubbles. Regions of interest were placed over the LAD and LCx beds in one of the aligned images, which were defined in vivo (see Experimental protocol). These were always drawn over the anterior half of the myocardial short axis (Fig. 3 ) to avoid any potential shadowing from microbubbles in the LV cavity and also to sample the myocardium at the same beam thickness. PI versus background-subtracted video intensity (VI) plots were generated for both regions of interest and fitted to the following exponential function: y ϭ A (1 Ϫ e Ϫ␤t ), where y is the VI at PI t, A is the plateau VI representing MBV, and ␤ is the rate of rise of VI representing the mean microbubble velocity. The product A ϫ ␤ represents MCE-derived MBF (30) . In addition, parametric images were also obtained by fitting the exponential function described above to the VI versus PI plot obtained for each pixel in the set of background-subtracted and aligned images (19) . These images were used to compare the topography of reduced MBV on MCE with that of the perfusion defect on ex vivo 99m Tc-sestamibi imaging. Experimental protocol. The LAD or LCx perfusion bed size was first defined in vivo using 0.1 ml of Albunex diluted to 1 ml with normal saline and injected subselectively into either artery. Figure 3A shows the method of defining the LAD bed. In group I dogs, LAD hyperemia was induced with a subselective intracoronary infusion of adenosine ranging in dose from 0.5 to 5.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 in different dogs (Fig. 1) . The purpose was to increase coronary blood flow to different degrees in separate dogs without causing systemic hemodynamic effects. After coronary blood flow had stabilized at the desired level, 99m Tc-sestamibi and radiolabeled microspheres were injected, and MCE was performed. In group II dogs, varying degrees of noncritical stenoses were placed either on the LAD or the LCx of different dogs, and their severity was determined by the transstenotic pressure gradient. MCE was performed at rest and subsequently repeated during hyperemia, at which time 99m Tc-sestamibi and radiolabeled microspheres were also injected intravenously. In group III dogs, resting MBF was reduced in either the LAD or LCX to different degrees in each dog with a flow-limiting stenosis. After coronary blood flow had stabilized, 99m Tc-sestamibi as well as radiolabeled microspheres were injected, and MCE was performed.
At the end of the experiment, the LAD bed was defined again by occlusion of the LAD and injection of Monastral blue dye (Sigma) into it. The dogs were euthanized using a mixture of pentobarbital sodium and KCl, and the heart was removed for processing. It was cut into five short-axis slices. The LAD bed was defined ex vivo as the region that was stained blue, whereas the LCx bed was unstained.
Statistical methods. Data are expressed as means Ϯ SD. Comparisons between stages were performed using either the paired or the unpaired Student's t-test. Correlations were performed using linear regression analysis. For differences among groups, a P value of Ͻ0.05 (two-sided) was considered significant.
RESULTS

Group I dogs.
There were small changes in heart rate (109 Ϯ 13 to 104 Ϯ 12 beats/min, P ϭ 0.02) and right atrial pressure (9 Ϯ 5 to 10 Ϯ 5 mmHg, P ϭ 0.04) without any changes in aortic or left atrial pressures during the subselective infusion of adenosine into the LAD. A wide range of flow mismatch between the LAD and LCx beds (range 1-4) was induced in separate dogs by using different doses of adenosine. Adenosine reduced the MVR in the LAD bed, which was associated with an increase in the mean MBF in the entire group of dogs by more than twofold (Table 1) . MBF in the control LCx bed remained unchanged during adenosine, although a slight decrease in CDP produced a small but significant decrease in MVR. No change in absolute plateau VI was noted between the hyperemic and control beds. Consequently, increases in MBF induced by adenosine were met by a corresponding increase in microbubble velocity (␤). Figure 4A shows an example of a MCE color-coded parametric image representing plateau VI (or MBV) from a group I dog where the LAD MBF was increased by approximately four times during subselective LAD infusion of adenosine, while the LCx MBF remained unchanged. The entire myocardium shows homogenous opacification, indicating a similar MBV in both the LAD and LCx beds despite the disparity in regional MBF. The corresponding 99m
Tc-sestamibi image of the same short-axis heart slice depicted in Fig. 4B also shows equal uptake of sestamibi in the entire myocardium. Figure 5 shows the relation between MBF and 99m Tc-sestamibi uptake from all group I dogs. Despite large increases in MBF to the LAD bed, the ratio of 99m Tc-sestamibi uptake between the two beds was flat. There was no difference in the ratio of 99m Tc sestamibi uptake in the myocardium versus the skeletal muscle for the LAD compared with the LCx bed (13 Ϯ 3 versus 15 Ϯ 3, P ϭ 0.37) despite a greater than twofold increase in MBF to the LAD bed.
Group II dogs. Infusion of adenosine into the left main coronary artery did not result in significant changes in heart rate or aortic and right atrial pressures, whereas the left atrial pressure increased slightly (from 14 Ϯ 2 to 17 Ϯ 4 mmHg, P ϭ 0.004). Because the stenoses were noncritical, MBF in the stenosed bed still increased during adenosine, although it was significantly less than that in the normal bed (Table 2) . Even though MVR in the stenosed bed decreased due to maximal arteriolar vasodilatation during adenosine, it did not decrease to the same extent as that in the group I dogs who had no stenosis (P Ͻ 0.01 between the two groups) because of a decrease in MBV distal to the stenosis during hyperemia.
MBF, microbubble velocity (␤), and MCE-derived MBF (A ϫ ␤) were similar at baseline in the beds with and without stenosis, resulting in ratios close to unity. During hyperemia, however, despite an absolute increase in these values in both beds, the relative change in the bed with stenosis was significantly less than that in the normal bed, resulting in lower ratios for these values in the stenosed versus control bed (Table 3) . In contradistinction to group I dogs, where regional differences in MBF were induced in the absence of changes in MBV (Fig. 4) , plateau VI decreased in group II dogs distal to the stenosis during hyperemia, indicating a reduction in MBV (A). Because MBV did not change in the normal bed during hyperemia, the MBV ratio between the stenosed and control beds decreased. Figure 6A shows a color-coded parametric image of plateau VI (or MBV) from a group II dog during hyperemia in whom MBF in the stenosed bed doubled from 1.0 to 2.0 ml ⅐ min Ϫ1 ⅐ g Ϫ1 with infusion of adenosine. The corresponding 99m Tc-sestamibi image from the same dog is shown in Fig. 6B . Similar to the parametric MCE image, a perfusion defect in the LAD bed is clearly seen despite an increase in the absolute LAD MBF during hyperemia. The perfusion defect corresponds in both location and spatial extent to the region with decreased MBV on the MCE image. The ratio of 99m Tc-sestamibi uptake in the myocardium versus the skeletal muscle was less for the stenosed LAD compared with the control LCx bed (12 Ϯ 4 versus 18 Ϯ 7, P ϭ 0.02) despite an almost twofold increase in MBF in the LAD bed.
A good correlation was noted between 99m
Tc-sestamibi uptake and plateau VI (MBV) ratios in the beds with and without stenosis in all group II dogs (Fig. 7A) . In this setting, where MBV decreased in the bed subtended by a stenosed artery and did not change in the bed supplied by a normal artery, a fair correlation was also found between 99m Tc-sestamibi uptake and the MBF ratios in the two beds (Fig. 7B) .
Group III dogs. Although the heart rate decreased slightly (from 108 Ϯ 14 to 103 Ϯ 13 beats/min, P ϭ 0.04) after placement of stenoses, no changes were noted in aortic, left, or right atrial pressures. The stenosis resulted in a 50% reduction in the CDP and a little Ͻ50% and resting MBF compared with baseline (Table 4) . MVR showed a mild decline, as did all the MCE parameters compared with the normal nonstenosed bed (Table 5) . Figure 8A illustrates an example of a color-coded parametric image from one group III dog with a flowlimiting LCx stenosis where the resting transstenotic pressure gradient was 60 mmHg and the resting MBF was reduced to 30% of normal. The resulting reduction in resting MBV caused a resting perfusion defect in the lateral wall. The corresponding 99m Tc-sestamibi image from the same dog in Fig. 8B shows an identical perfusion defect secondary to lower uptake of sestamibi in the stenosed compared with normal bed. In dogs in whom the stenosed versus control resting MBF was Ͻ1, the ratio of 99m Tc-sestamibi uptake in the myocardium versus the skeletal muscle was significantly less for the stenosed compared with control bed (6.5 Ϯ 3 versus 15 Ϯ 3, P ϭ 0.007).
An excellent correlation was found between the ratios of resting 99m Tc-sestamibi activity and MBV (A) in the beds with and without stenosis (Fig. 9A) . Because the decrease in resting MBV was associated with a decrease in resting MBF, a good correlation was also noted between the 99m Tc-sestamibi activity versus radiolabeled microsphere-derived MBF ratios from the beds with and without stenosis (Fig. 9B) .
DISCUSSION
The new finding from this study is that reversible 99m Tc-sestamibi perfusion defects during coronary vasodilatation occur due to a reversible decrease in MBV distal to a stenosis rather than to a MBF mismatch. We also found that 99m Tc-sestamibi uptake does not increase during coronary hyperemia when MBV remains unchanged and that it decreases when MBV is reduced irrespective of the direction of change in MBF. Taken together, these findings indicate that 99m Tc-sestamibi uptake reflects MBV and not MBF.
In this study, we used MCE to define MBV. This approach is based on the concept that when steady state is achieved, the tissue concentration of a pure intravascular tracer reflects the blood volume of that tissue. We have shown that microbubbles of the type used in this study remain entirely within the intravascular space and have an intravascular rheology as well 
Values are means Ϯ SD.
as a myocardial transit rate that is similar to that of red blood cells (14, 17) . We (30) have also shown that at the concentrations used in this study, the relation between microbubble concentration and VI is linear. Linka et al. (20) demonstrated that the changes in total tissue blood volume are associated with changes in microbubble transit rate. Thus the method used appears to be accurate and provides a transmural distribution of MBV.
Gould et al. (8) first demonstrated that hyperemic coronary blood flow was attenuated in the presence of stenoses that exceeded 50% of the coronary luminal diameter. At about the same time, it became clear that in the presence of Ͼ50% coronary stenosis, reversible defects could be seen on exercise myocardial perfusion imaging with the use of radioisotopes (1, 29) . Thus it was believed that reversible perfusion defects during hyperemia were secondary to MBF mismatch that developed between the beds with and without stenosis. This belief has persisted despite repeated demonstration of a relatively flat relation between MBF and isotope uptake at levels of hyperemic flow, particularly with 99m Tc-labeled tracers ( Fig. 10) (6, 7) . Capillaries do not have vascular smooth muscle. As a consequence, it has always been assumed that capillary dimensions (and thus resistance) do not change with changes in coronary blood flow. When a coronary vasodilator is administered into the normal coronary circulation, MBV (volume of blood within the myocardial microvasculature, 90% of which is in capillaries; see Ref. 16 ) does not change despite an increase in MBF (3, 4, 30) . The latter occurs solely due to an increase in MBF velocity caused by a decrease in arteriolar and, to a smaller extent, venular resistance. Thus, in the normal coronary circulation, capillary dimensions do not change during exogenously mediated hyperemia, whereas the arteriolar and venular dimensions increase (9, 15) .
With the use of MCE, we have recently shown that, even though arterioles are the site of greatest resistance at rest, capillaries offer the greatest resistance during hyperemia (13) . Thus increases in hyperemic Tc-sestamibi image (B) from a group II dog with a moderate LAD stenosis during hyperemia. A perfusion defect can be seen in the LAD bed on the 99m Tc-sestamibi image that corresponds closely to the area with reduced myocardial blood volume (MBV) on MCE despite a twofold increase in MBF to the LAD bed. MBF in the normal coronary circulation are limited primarily by capillary resistance. Even in the presence of a stenosis, it is capillary resistance (and not stenosis resistance) that mostly limits increases in peak hyperemic MBF (13) . Although MBV remains constant in the absence of a stenosis during hyperemia, it decreases in the presence of a stenosis, and this decrease in MBV is proportional to the severity of the stenosis (13) .
The results of our present study demonstrate that when regional MBV remains constant, Tc-sestamibi uptake does not change despite an increase of several degrees in regional MBF. Thus a disparity in isotope uptake during hyperemia cannot be explained on the basis of differences in MBF alone. Our results also show that tracer uptake decreases in proportion to the decrease in MBV independent of the change in absolute MBF (an increase as in group II dogs or a decrease as in group III dogs). Furthermore, group I dogs demonstrated less reduction in 99m Tc-sestamibi uptake for any given reduction in MBF (Fig. 6B ) and a closer correlation was noted between 99m Tc-sestamibi uptake and MBV. Thus reversible perfusion defects on 99m Tcsestamibi imaging are caused by changes in MBV and not MBF.
Because it is not possible to determine absolute MBF with the use of 99m Tc-sestamibi, we could only express 99m Tc-sestamibi uptake in relative terms. To show that 99m Tc-sestamibi uptake had not increased in the hyperemic LAD in the group I dogs and had actually decreased in the stenosed bed during hyperemia in the group II dogs and at rest in the group III dogs, we measured 99m Tc-sestamibi uptake in the skeletal muscle as well. We assumed that changes in MBF did not affect skeletal muscle flow. With the use of the skeletal muscle as a "reference organ," we showed that the 99m Tc-sestamibi uptake in the LAD bed did not increase during adenosine infusion in the group I dogs. We also demonstrated reduced 99m Tc-sestamibi uptake in the stenosed bed in the group II and III dogs. Although these measurements still reflect only relative uptake, we would not expect skeletal muscle uptake of 99m Tc-sestamibi not be affected by change in MBF when systemic hemodynamics remained stable between stages.
The data points in Fig. 10 shows the relation between MBF and 99m Tc-sestamibi uptake ratios be- Tc-sestamibi image (B) from a group III dog during resting hypoperfusion. Both images show a similar perfusion defect in the lateral myocardium. The posteromedial papillary muscle was not included in the heart slice used to generate the 99m Tc-sestamibi image. Tc-sestamibi uptake from their results compared with the virtually flat relation from ours could be related to the use of intravenous rather than intracoronary administration of adenosine in the former. Hypotension in anesthetized dogs as well as a direct effect on adenosine A 1 receptors causes tachycardia, which increases myocardial O 2 consumption and which in turn increases MBV (18) via capillary recruitment required for adequate myocyte oxygen delivery (5, 10) . The increase in MBV could in turn allow an increase in 99m Tc-sestamibi uptake. That capillary blood volume modulates tracer uptake should not be surprising. The extraction fraction of a tracer is proportional to the permeability-surface area product (2) . The second component of this product represents the surface area available for nutrient exchange between capillaries and myocytes, which is directly related to capillary blood volume. Thus when permeability-related factors are constant, the main determinant of extraction fraction becomes the capillary blood volume. Consequently, a decrease in capillary blood volume should result in a proportionate decrease in tracer uptake. Other factors that can effect the permeability-surface area product, such as the magnitude of MBF, are constant for 99m Tc-sestamibi (21). In the model of noncritical coronary stenosis used in our study, the myocyte membrane properties that affect lipophilicity (27) , the mitochondrial negative potential that determines 99m Tc-sestamibi myocyte retention (24, 25) , and the physical attributes of the tracer itself should not be different in various myocardial regions. Taken together, these findings imply that differences in regional Tc-sestamibi uptake during coronary vasodilatation are related mainly to regional differences in capillary blood volume.
In addition to providing mechanistic insights into the role of capillaries in coronary blood flow regulation, our results also raise important questions regarding measurement of MBF with tracers. Radiolabeled microspheres are considered to be the best because they are completely entrapped in the coronary microcirculation (99% extraction fraction) (11, 28) . Thus even if capillary blood volume changes, tracer uptake will remain proportional to MBF. MBF would not, however, be reflected accurately by tracers whose uptake depends on diffusion across the capillary bed, for reasons discussed above, and would instead reflect MBV.
A case in point is 201 Tl, whose uptake versus MBF relation during hyperemia is shown as line B in Fig. 10  (7) . The uptake (U) of a tracer depends on the rate of supply [the product of arterial concentration (C) and flow (F)] as well as the rate of diffusion across the capillaries [determined by the permeability-surface area product (PS)] given by the following formula: U ϭ C ϫ F[1 Ϫ e (ϪPS/F) ]. At low flows, if there is no decrease in MBV, then because PS ϾϾ F, the above formula reduces to U ϭ C ϫ F and, therefore, U is proportional to flow. At high flows, PS ϽϽ F, and the above formula reduces to U ϭ C ϫ PS and, therefore, U is proportional to PS and is independent of flow. Because the PS is greater for the more diffusible tracer 201 Tl than 99m Tc-sestamibi, the relation between MBF and tracer uptake is more linear for 201 Tl (line B in Fig. 10) . However, the uptake of even a highly diffusible tracer like 201 Tl will plateau at higher flows during hyperemia (line B in Fig. 10 ) because, as shown in this and previous studies, the capillary blood volume does not increase appreciably during exogenously induced hyperemia.
Unlike exogenously induced hyperemia, where myocardial O 2 consumption does not change significantly, hyperemia induced by exercise is associated with increased myocardial O 2 demand, which in turn results in capillary recruitment and increased MBV (18) . In this setting, PS increases with an increase in MBF, resulting in greater tracer uptake even at a higher MBF (line C in Fig. 10 ). Thus capillary recruitment could explain the apparent disparity between the results of Neilson et al. (22) (depicted as line C in Fig. 10 ), who measured 201 Tl uptake in exercising dogs, and those of others (7, 18) , who measured it during exogenously induced coronary hyperemia. Therefore, unlike tracers that are trapped in the microcirculation, the uptake of diffusible tracers is determined by the status of myocardial capillaries. It is likely, therefore, that the uptake of 99m Tc-sestamibi also increases during exercise in the normal myocardium where capillaries can be recruited, although because of its poor diffusion the increase will be significantly less than that of 201 Tl.
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